Bristol-Myers Squibb Company (BMY) Earnings History
Profitable37 years of earnings data (1989–2025) · Positive TTM net income
Loading earnings history...
Bristol-Myers Squibb Company (BMY) Earnings Overview
As of June 21, 2026, Bristol-Myers Squibb Company (BMY) reported trailing twelve-month net income of $7.28B, reflecting +178.2% year-over-year growth. The company earned $3.56 per diluted share over the past four quarters, with a net profit margin of 14.6%.
Looking at the long-term picture, BMY's historical earnings data spans multiple years. The company achieved its highest annual net income of $10.61B in fiscal 2009.
Bristol-Myers Squibb Company maintains positive profitability with a gross margin of 67.6%, operating margin of 26.3%, and net margin of 14.6%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including PFE ($7.49B net income, 12.4% margin), MRK ($18.25B net income, 28.1% margin), ABBV ($4.23B net income, 6.9% margin), BMY has outperformed on profitability metrics. Compare BMY vs PFE →
BMY Earnings vs Peers
Earnings metrics vs comparable public companies
BMY Historical Earnings Data (1989–2025)
37 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7.05B | +178.8% | $12.70B | $3.45 | 14.6% | 26.3% |
| 2024 | -$8.95B | -211.5% | $9.66B | $-4.41 | -18.5% | 20.0% |
| 2023 | $8.03B | +26.8% | $8.47B | $3.86 | 17.8% | 18.8% |
| 2022 | $6.33B | -9.5% | $9.27B | $2.95 | 13.7% | 20.1% |
| 2021 | $6.99B | +177.8% | $9.54B | $3.12 | 15.1% | 20.6% |
| 2020 | -$8.99B | -361.6% | $4.49B | $-3.98 | -21.2% | 10.6% |
| 2019 | $3.44B | -30.1% | $6.44B | $2.01 | 13.2% | 24.6% |
| 2018 | $4.92B | +388.6% | $6.39B | $3.03 | 21.8% | 28.3% |
| 2017 | $1.01B | -77.4% | $5.24B | $0.61 | 4.8% | 25.2% |
| 2016 | $4.46B | +184.8% | $5.18B | $2.65 | 22.9% | 26.7% |
| 2015 | $1.56B | -21.9% | $3.94B | $0.97 | 9.5% | 23.8% |
| 2014 | $2.00B | -21.8% | $3.13B | $1.20 | 12.6% | 19.7% |
| 2013 | $2.56B | +30.8% | $3.13B | $1.54 | 15.6% | 19.1% |
| 2012 | $1.96B | -47.2% | $4.27B | $1.16 | 11.1% | 24.2% |
| 2011 | $3.71B | +19.6% | $6.75B | $2.16 | 17.5% | 31.8% |
| 2010 | $3.10B | -70.8% | $6.14B | $1.80 | 15.9% | 31.5% |
| 2009 | $10.61B | +102.2% | $5.05B | $5.37 | 56.4% | 26.8% |
| 2008 | $5.25B | +142.4% | $4.88B | $2.62 | 25.5% | 23.7% |
| 2007 | $2.17B | +36.6% | $3.77B | $1.09 | 11.2% | 19.5% |
| 2006 | $1.58B | -47.2% | $2.64B | $0.81 | 8.8% | 14.7% |
| 2005 | $3.00B | +25.6% | $4.13B | $1.51 | 15.6% | 21.5% |
| 2004 | $2.39B | -23.1% | $4.70B | $1.21 | 12.3% | 24.2% |
| 2003 | $3.11B | +45.3% | $4.93B | $1.59 | 14.9% | 23.6% |
| 2002 | $2.14B | -55.8% | $4.10B | $1.02 | 11.8% | 22.6% |
| 2001 | $4.83B | +2.6% | $5.16B | $2.67 | 24.9% | 26.6% |
| 2000 | $4.71B | +13.1% | $5.99B | $2.36 | 25.9% | 32.9% |
| 1999 | $4.17B | +32.7% | $5.24B | $2.06 | 20.6% | 25.9% |
| 1998 | $3.14B | -2.0% | $4.46B | $1.55 | 17.2% | 24.4% |
| 1997 | $3.21B | +12.5% | $4.44B | $1.57 | 19.2% | 26.6% |
| 1996 | $2.85B | +57.3% | $3.95B | $1.40 | 18.9% | 26.2% |
| 1995 | $1.81B | -1.6% | $3.62B | $0.89 | 13.2% | 26.3% |
| 1994 | $1.84B | -6.0% | $3.22B | $0.90 | 15.4% | 26.9% |
| 1993 | $1.96B | -0.2% | $2.40B | $0.95 | 17.2% | 21.1% |
| 1992 | $1.96B | -4.6% | $1.96B | $0.96 | 17.6% | 17.6% |
| 1991 | $2.06B | +17.6% | $2.77B | $0.99 | 18.4% | 24.8% |
| 1990 | $1.75B | +134.0% | $2.39B | $0.84 | 17.0% | 23.2% |
| 1989 | $747M | - | $1.08B | $0.36 | 8.1% | 11.8% |
Download Data
Export BMY earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into BMY consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
37+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BMY — Frequently Asked Questions
Quick answers to the most common questions about buying BMY stock.
What is BMY earnings per share (EPS)?
BMY trailing twelve-month (TTM) diluted EPS is $3.56, reflecting +178.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1989 to 2025 is available in the table on this page.
What is Bristol-Myers Squibb Company's net income?
Bristol-Myers Squibb Company (BMY) trailing twelve-month net income is $7.3B as of 2025. Earnings grew +178.2% year-over-year.
Is BMY profitable?
Yes, BMY is profitable with a TTM net income of $7.3B and a net profit margin of +14.6%.
What is BMY's earnings growth rate?
BMY compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: +5.4%, 5-Year: N/A, 10-Year: +13.5%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1989 to 2025.
What are BMY's profit margins?
Bristol-Myers Squibb Company net profit margin is +14.6%, operating margin is +26.3%, and gross margin is +67.6%. Margins are within a typical range for the sector. Return on Equity is +40.4%.
Is BMY growing earnings?
Yes, BMY earnings are accelerating — EPS growth of +178.2% exceeds the 5-year CAGR of N/A. TTM net income reached $7.3B. Earnings momentum is strengthening.
What was BMY's best earnings year?
Bristol-Myers Squibb Company's highest annual net income on record is $10.6B, achieved in fiscal year 2009. Earnings history on this page spans 1989 to 2025 and includes all annual and quarterly figures.
What were BMY's earnings last quarter?
BMY's most recent reported quarter was Q1 2026. Net income was $2.7B with diluted EPS of $1.31. For a full breakdown of all quarters, see the quarterly earnings table on this page.